全文获取类型
收费全文 | 146842篇 |
免费 | 32382篇 |
国内免费 | 2388篇 |
专业分类
耳鼻咽喉 | 5153篇 |
儿科学 | 5322篇 |
妇产科学 | 2348篇 |
基础医学 | 2844篇 |
口腔科学 | 1457篇 |
临床医学 | 26422篇 |
内科学 | 46483篇 |
皮肤病学 | 7274篇 |
神经病学 | 14602篇 |
特种医学 | 6291篇 |
外科学 | 40616篇 |
综合类 | 227篇 |
现状与发展 | 72篇 |
预防医学 | 6867篇 |
眼科学 | 3311篇 |
药学 | 835篇 |
中国医学 | 6篇 |
肿瘤学 | 11482篇 |
出版年
2023年 | 4775篇 |
2022年 | 1146篇 |
2021年 | 3031篇 |
2020年 | 5997篇 |
2019年 | 2114篇 |
2018年 | 7332篇 |
2017年 | 7294篇 |
2016年 | 8367篇 |
2015年 | 8354篇 |
2014年 | 15414篇 |
2013年 | 15521篇 |
2012年 | 5317篇 |
2011年 | 5318篇 |
2010年 | 10261篇 |
2009年 | 14161篇 |
2008年 | 5651篇 |
2007年 | 3875篇 |
2006年 | 6351篇 |
2005年 | 3637篇 |
2004年 | 2911篇 |
2003年 | 1894篇 |
2002年 | 1984篇 |
2001年 | 3752篇 |
2000年 | 2974篇 |
1999年 | 3180篇 |
1998年 | 3615篇 |
1997年 | 3384篇 |
1996年 | 3340篇 |
1995年 | 3191篇 |
1994年 | 1931篇 |
1993年 | 1555篇 |
1992年 | 1346篇 |
1991年 | 1399篇 |
1990年 | 1048篇 |
1989年 | 1169篇 |
1988年 | 1007篇 |
1987年 | 831篇 |
1986年 | 880篇 |
1985年 | 710篇 |
1984年 | 541篇 |
1983年 | 514篇 |
1982年 | 507篇 |
1981年 | 392篇 |
1980年 | 354篇 |
1979年 | 306篇 |
1978年 | 328篇 |
1977年 | 396篇 |
1975年 | 277篇 |
1972年 | 279篇 |
1970年 | 253篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
52.
53.
54.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
55.
56.
57.
58.
Loren Saulsberry PhD Ankur Bhargava MD MPH Sharon Zeng BA Jason B. Gibbons PhD Cody Brannan MS Diane S. Lauderdale PhD Robert D. Gibbons PhD 《Health services research》2023,58(4):873-881
Objective
To derive and validate a new ecological measure of the social determinants of health (SDoH), calculable at the zip code or county level.Data Sources and Study Setting
The most recent releases of secondary, publicly available data were collected from national U.S. health agencies as well as state and city public health departments.Study Design
The Social Vulnerability Metric (SVM) was constructed from U.S. zip-code level measures (2018) from survey data using multidimensional Item Response Theory and validated using outcomes including all-cause mortality (2016), COVID-19 vaccination (2021), and emergency department visits for asthma (2018). The SVM was also compared with the existing Centers for Disease Control and Prevention's Social Vulnerability Index (SVI) to determine convergent validity and differential predictive validity.Data Collection/Extraction Methods
The data were collected directly from published files available to the public online from national U.S. health agencies as well as state and city public health departments.Principal Findings
The correlation between SVM scores and national age-adjusted county all-cause mortality was r = 0.68. This correlation demonstrated the SVM's robust validity and outperformed the SVI with an almost four-fold increase in explained variance (46% vs. 12%). The SVM was also highly correlated (r ≥ 0.60) to zip-code level health outcomes for the state of California and city of Chicago.Conclusions
The SVM offers a measurement tool improving upon the performance of existing SDoH composite measures and has broad applicability to public health that may help in directing future policies and interventions. The SVM provides a single measure of SDoH that better quantifies associations with health outcomes. 相似文献59.
60.